2006
DOI: 10.1093/ajcn/84.5.971
|View full text |Cite
|
Sign up to set email alerts
|

Lutein and zeaxanthin intakes and risk of age-related macular degeneration and cataracts: an evaluation using the Food and Drug Administration’s evidence-based review system for health claims

Abstract: The labeling of health claims that meet the significant scientific agreement standard and of qualified health claims on conventional foods and dietary supplements requires premarket approval by the Food and Drug Administration (FDA). The FDA conducts an evidence-based review to ascertain whether sufficient evidence exists to support a significant scientific agreement standard or a qualified health claim. The FDA recently reviewed intervention and observational studies that evaluated the role of lutein and zeax… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
37
0
4

Year Published

2008
2008
2016
2016

Publication Types

Select...
4
3
2

Relationship

0
9

Authors

Journals

citations
Cited by 88 publications
(41 citation statements)
references
References 41 publications
0
37
0
4
Order By: Relevance
“…In 2006, the Food and Drug Administration concluded that there was no credible evidence to support a health claim for lutein or zeaxanthin intake in relation to the risk of AMD ( 14 ). However, the National Eye Institute started a new randomized clinical trial called the Age-Related Eye Disease Study 2, designed to evaluate the effects of nutrients including lutein on the development of AMD ( 15 ).…”
mentioning
confidence: 99%
“…In 2006, the Food and Drug Administration concluded that there was no credible evidence to support a health claim for lutein or zeaxanthin intake in relation to the risk of AMD ( 14 ). However, the National Eye Institute started a new randomized clinical trial called the Age-Related Eye Disease Study 2, designed to evaluate the effects of nutrients including lutein on the development of AMD ( 15 ).…”
mentioning
confidence: 99%
“…The US Food and Drug Administration (FDA) has conducted an evidence-based review to evaluate the role of lutein and zeaxanthin in reducing the risk of AMD 62 . After reviewing a number of intervention and observational studies, the FDA denied a health claim about the intake of lutein or zeaxanthin (or both) and the risk of AMD in 2006.…”
Section: Carotenoids (β-Carotene Lutein and Zeaxanthin)mentioning
confidence: 99%
“…Entretanto, seus efeitos benéficos na degeneração macular permanecem controversos. O Food and Drug Administration (FDA) conduziu uma revisão de estudos para averiguar e ter a certeza sobre as evidências científicas do papel da luteína e zeaxantina na degeneração macular e cataratas (40) . Com base nas revisões, o FDA concluiu que não existem evidências fidedignas sobre a atuação da luteína e zeaxantina sobre o risco de degeneração macular e/ou catarata (41) .…”
Section: Antioxidantes Sintéticosunclassified